First TREAT™ Trispecific Antibody Targeting BCMA and CD38,
ISB 2001, is on Track to Enter Clinical Development in 2023
NEW YORK, May 9, 2022 /PRNewswire/ — Ichnos Sciences Inc., a clinical-stage global biotechnology company developing innovative multispecific antibodies for oncology, today announced the selection of ISB 2001, its first TREAT1 trispecific antibody, which engages BCMA x CD38 x CD3, as its next candidate to move into clinical development. The company has initiated IND-enabling studies for relapsed/refractory multiple myeloma and aims to advance ISB 2001 to a first-in-human study once clearance from the health authorities is received in 2023.
ISB 2001 is the first T cell-engaging antibody that targets BCMA and CD38 on multiple myeloma cells. It is a trispecific antibody based on BEAT® 2.0 technology2, a proprietary platform allowing maximal flexibility and manufacturability of full length multispecific antibodies. Additional ISB 2001 details include:
“This milestone represents another exciting step forward as Ichnos moves its first trispecific antibody targeting BCMA and CD38 into IND-enabling studies for relapsed/refractory multiple myeloma,” said Cyril Konto, M.D., President and CEO of Ichnos. “We have made tremendous progress with our proprietary BEAT® 2.0 platform and are excited about advancing our first TREAT trispecific antibody candidate to clinic in 2023.”
Ichnos’ pipeline continues to expand, and the selection of ISB 2001 as Ichnos’ next clinical candidate follows the decision to advance ISB 1442, a CD38 x CD47 biparatopic bispecific antibody for hematologic malignancies, in August 2021. A first-in-human study with ISB 1442 is planned to start in mid-2022. Ichnos’ lead clinical candidate, ISB 1342, a CD38 x CD3 bispecific antibody, continues to enroll patients with relapsed/refractory multiple myeloma in an ongoing Phase 1, dose escalation and expansion study.
About Ichnos Sciences Inc.
A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT® technology platform and pioneering teams, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.
For more information, visit IchnosSciences.com.
Head of Communications and Corporate Affairs
1 TREAT™: Trispecific Engagement by Antibodies based on the TCR
2 BEAT®: Bispecific Engagement by Antibodies based on the TCR
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.